Nijenhuis VJ, Brouwer J, Delewi R, et al. - This study was undertaken to investigate the roles of anticoagulation alone or with an antiplatelet agent after transcatheter aortic-valve implantation (TAVI). A randomized trial of clopidogrel was conducted in patients undergoing TAVI who were receiving oral anticoagulation for appropriate indications. Individuals were allocated before TAVI in a 1:1 ratio not to receive clopidogrel or to receive clopidogrel for 3 months.  Researchers enrolled a total of 157 patients. The study found lower incidence of serious bleeding over a period of 1 month or 1 year with oral anticoagulation alone than with oral anticoagulation plus clopidogrel in patients undergoing TAVI who were receiving oral anticoagulation.